Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad drug to enter brain cancer trial
This new human clinical study will evaluate the potential of MPC-6827 to treat metastatic brain cancer by achieving therapeutic concentrations in the brain that are sufficient to treat
This new human clinical study will evaluate the potential of MPC-6827 to treat metastatic brain cancer by achieving therapeutic concentrations in the brain that are sufficient to treat
The National Institute of Clinical Excellence (NICE) has recommended that four cholinesterase inhibitors currently licensed in the UK for use in Alzheimer’s disease, donepezil (Pfizer and Eisai’s Aricept),
Under the terms of this agreement, 3M and Takeda will share further costs of development and, upon successful clinical development and regulatory approvals, the companies will jointly commercialize
Increased platelet activation is a feature of diabetes that contributes to the high incidence of cardiovascular events in diabetic patients. NCX 4016 is a novel antithrombotic and vascular
MN-305 is described as a serotonin type 1A receptor agonist, and based on preclinical and earlier clinical studies, could hold the potential for rapid onset of anti-anxiety effect
Sunesis’ Aurora kinase inhibitors target cells in the mitotic phase of the cell cycle. In vivo results demonstrate robust activity, including significant tumor growth retardation, exceeding 80% in
Anthim is a therapeutic monoclonal antibody being developed by Elusys to prevent and treat anthrax infections. Following clearance of the investigational new drug (IND) by the FDA, Elusys
The principal purpose of the phase I clinical trial is to establish the safety of the VRX496 therapy in patients failing two or more HAART regimens. Each of
In its preliminary results statement of January 19 2005, GW announced that it would embark on a regulatory program in the US for its lead product, Sativex. The
The studies examined the anticoagulant and antiplatelet activities of MC-45308 in both in vitro and in vivo experiments. The anticoagulant effects of MC-45308 were evaluated with a series